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Asymptomatic Seroconversion of Immunoglobulins
to SARS-CoV-2 in a Pediatric Dialysis Unit
Dialysis units are at especially high risk of infectious disease
transmission, and concern exists about spreadof severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Dialysis
units in Wuhan, China, have reported high coronavirus dis-
ease 2019 (COVID-19) preva-
lence, due in part to unique
exposurechallenges that limit
social distancing efforts, including open bay formats and ro-
tating/multiple nursing assignments.1,2 This study describes
SARS-CoV-2 seroconversion in patients andhealth carework-
ers in a pediatric dialysis unit.
Methods |Serial SARS-CoV-2antibody levelsweremeasured in
patients, nurses, physicians, and staff in a freestanding out-
patient 5-bed/3–isolation roompediatric hemodialysis unit at
Riley Hospital for Children, Indianapolis, Indiana. Hemodi-
alysis occurs during 2 shifts onMonday,Wednesday, and Fri-
day. All patients had temperature and symptomsof COVID-19
screenedbeforeentry.Patientsworesurgicalmasksatall times,
asdidhealthcareworkers,whoalsohad temperatureschecked
before and after shifts.
Oneweekbefore this studybegan (day0;March25, 2020),
a single patient presented with fever and generalized symp-
toms.A reverse transcriptase–polymerasechain reaction (PCR)
test result for SARS-CoV-2onanasopharyngeal swabwasposi-
tive, and results on subsequent swabs remained positive on
days 7 and 14until day 19 (April 11, 2020). Thepatientwasdia-
lyzed in an isolation roomonday0and thereafter. Serum IgM
and IgG levels were measured on sera from whole blood
samples fromall studyparticipants ondays 7, 14, and21 (April
1, 2020, to April 15, 2020) using SARS-CoV-2 enzyme-linked
immunosorbent assays (ELISAs) (#KA5826, Abnova). Confir-
matory ELISAs were performed at Mount Sinai Medical Cen-
ter.Manufacturer’s instructionswere followed forELISAs and
confirmatory tests as previously published.3 We determined
the threshold for apositiveELISA result at0.14, a valuegreater
than the mean plus 3 times the standard deviation of nega-
tive control, consistent with standardmethodology andwith
serumvaluesofPCR-confirmedpositive controlpatients.4Par-
ticipantswere considered tohave seroconverted if positive for
IgMor IgG. TheELISA sensitivity and specificitywerenot pro-
vided by the manufacturer.
All participants (or legal representatives) provided writ-
ten or verbal consent to participate. Human subjects ap-
proval was obtained through the Indiana University institu-
tional review board.
Results | Thirteen patients, 9 dialysis nurses, 2 nurse practi-
tioners, 4 staff, and 10 physicians participated in the study.
All participant characteristics and results are presented in
the Table. Between day 0 and day 7, 2 health care workers
had negative PCR test results despite upper respiratory tract
symptoms and fevers. One of these health care workers
subsequently seroconverted on day 21 despite 3 negative
PCR results. No other study participants had nasopharyn-
geal testing or symptomatology consistent with COVID-19
before day 7.
By day 21, 11 of 25 health care workers (44%) and 3 of 13
patients (23%) had positive SARS-CoV-2 antibodies (Figure).
No participants developed symptoms between days 7 and 21.
No health care workers who directly cared for the PCR-
positive patient seroconverted.
Twoof 11healthcareworkerswhocared for2patientswith
subclinical seroconversion developed SARS-CoV-2 antibod-
ies.Bothhealth careworkers remainedasymptomatic, butone
had a positive result on a nasopharyngeal PCR test obtained
because of IgM seroconversion.
Discussion | This study found a high prevalence of subclinical
seroconversion in individuals interacting in a pediatric
dialysis unit. To our knowledge, no other studies of sero-
conversion in health care settings exist. The 1 symptomatic,
PCR-positive patient may have been the source of spread,
but other health care environment or community transmis-
sion cannot be ruled out. The prevalence of subclinical sero-
conversion in the health care workers suggests that more
health care workers may be antibody-positive than would
otherwise be expected. Information on seroprevalence can
Table. Characteristics and Cumulative SARS-CoV-2 Seroconversion
for Patients Receiving Dialysis and Health CareWorkers
Characteristic
No. (%)
Patients (n = 13)
Health care
workers (n = 25)a
Age, median (range), y 13 (2-16) 40.5 (25-61)
Male sex 9 (69) 3 (12)
Serostatus by week 3
IgM+ 2 (15) 7 (28)
IgG+ 3 (23) 4 (16)
IgM+ or IgG+ 3 (23) 11 (44)
COVID-19–like symptoms 1 (8) 2 (8)
Positive PCR (symptomatic)b 1 (100) 0
Asymptomatic IgM positive 1 (8) 4 (16)
Positive PCR (asymptomatic)c 0 1 (25)
Abbreviations: COVID-19, coronavirus disease 2019; PCR, polymerase chain
reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a Health care workers include 9 dialysis nurses, 2 nurse practitioners, 4 staff,
and 10 physicians.
b PCR testing was performed on patients or health care workers with
COVID-19–like symptoms (n = 3).
c PCR testing was performed on asymptomatic patients or health care workers
with IgM and no IgG (n = 5).
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allow strategically staffing the care of SARS-CoV-2–positive
or patients suspected to be positive with seroconverted
nurses and physicians. This study has limitations including
a small sample size, short follow-up, lack of large-scale
sensitivity/specificity of ELISA, lag of antibody positivity
from PCR positivity, and the setting of a single pediatric
dialysis unit.
Replication in additional sites is needed to define the
broad applicability of these findings, as is longer-term follow
up to determine the persistence of the antibody response
to SARS-CoV-2.
David S. Hains, MD
Andrew L. Schwaderer, MD
Aaron E. Carroll, MD, MS
Michelle C. Starr, MD, MPH
Amy C. Wilson, MD
Fatima Amanat, MA
Florian Krammer, PhD
Author Affiliations:Department of Pediatrics, Indiana University, Indianapolis
(Hains, Schwaderer, Carroll, Starr, Wilson); Department of Microbiology, Icahn
School of Medicine at Mount Sinai Medical Center, New York, New York
(Amanat, Krammer).
Corresponding Author:David S. Hains, MD, Riley Hospital for Children, Indiana
University School of Medicine, 699 Riley Hospital Dr, RR230, Indianapolis, IN
46202 (dhains@iu.edu).
Accepted for Publication:May 5, 2020.
Published Online:May 14, 2020. doi:10.1001/jama.2020.8438
Author Contributions:Dr Hains had full access to all of the data in the study
and takes responsibility for the integrity of the data and the accuracy of the data
analysis.
Concept and design:Hains, Schwaderer, Starr, Wilson, Krammer.
Acquisition, analysis, or interpretation of data:Hains, Schwaderer, Carroll, Starr,
Wilson, Amanat.
Drafting of the manuscript:Hains, Schwaderer, Wilson, Amanat.
Critical revision of the manuscript for important intellectual content:Hains,
Schwaderer, Carroll, Starr, Wilson, Krammer.
Statistical analysis:Hains, Starr, Wilson, Amanat.
Obtained funding: Schwaderer.
Administrative, technical, or material support:Hains, Schwaderer, Carroll, Starr,
Wilson, Krammer.
Supervision:Hains, Schwaderer, Carroll.
Conflict of Interest Disclosures:Dr Schwaderer reported receiving grants from
Eli Lilly Foundation and the National Institutes of Health. Dr Krammer reported
that a patent to The Icahn School of Medicine at Mount Sinai is in the process of
licensing assays based on the assays described herein to commercial entities
and that the school of medicine has filed for patent protection, pending and
licensed. No other authors reported disclosures.
Funding/Support: The study was supported by the Lilly Endowment Inc
Physician Scientist Initiative to Drs Hains and Schwaderer. Dr Krammer was
supported by institutional seed funding.
Role of the Funder/Sponsor: The Lilly Endowment Inc Physician Scientist
Initiative had no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; preparation, review, or
approval of themanuscript; and decision to submit themanuscript for
publication.
Additional Contributions: The following individuals collaborated in study
development and data collection and participated in drafting or review of the
manuscript: Corina Nailescu, MD, Myda Khalid, MD, SherryWilson, RN, Ashley
Rawson, MD, Elizabeth Spiwak, MD, Bethanne Johnston, RN, NP, Lindsay
Berman, RN, NP, Sushil Gupta, MD, Jenaya Hooks, BS, Samuel Arregui, BS, Jorge
Canas, BS, Neha Pottanat, MD, John Christenson, MD, Molly Jackson, RN,
Courtney Conner, RN, Ashley Thomas, RN, Shannon Stewart, RN, Justice
Cornelius, Shannon Anderson, RN, Danielle Lowden, RN, Suzanne Hedrick, RN,
Naomi Rivera, Laura Ruhe, RN, Erica McNary, RN, Susan Campbell, RN (Indiana
University School of Medicine, Indianapolis, Indiana); Parnavi Desai, MS (Icahn
School of Medicine at Mount Sinai Medical Center, New York, New York). None
of these individuals received any compensation for their contributions.
1. Su K, Ma Y, Wang Y, et al. Howwemitigate and contain COVID-19 outbreak in
hemodialysis center (HD): lessons and experiences. Infect Control Hosp Epidemiol.
Published online April 23, 2020. doi:10.1017/ice.2020.161
2. Kliger AS, Silberzweig J. Mitigating risk of COVID-19 in dialysis facilities. Clin J
Am Soc Nephrol. 2020;15(5):707-709. doi:10.2215/CJN.03340320
3. Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 seroconversion in
humans: a detailed protocol for a serological assay, antigen production, and test
setup. Curr Protoc Microbiol. 2020;57(1):e100. doi:10.1002/cpmc.100
4. Luo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose
novel coronavirus disease (COVID-19). Clin Infect Dis. Published online March 21,
2020. doi:10.1093/cid/ciaa310
Seroprevalence of SARS-CoV-2–Specific Antibodies
AmongAdults in Los Angeles County, California,
on April 10-11, 2020
Inadequateknowledgeabout theextentof thecoronavirusdis-
ease 2019 (COVID-19) epidemic challenges public health re-
sponse andplanning.Most reports of confirmed cases rely on
polymerase chain reaction–based testing of symptomatic
patients.1 These estimates of
confirmed cases miss indi-
viduals who have recovered
frominfection,withmildornosymptoms,and individualswith
symptomswho have not been tested due to limited availabil-
ity of tests.
We conducted serologic tests in a community sample to
estimate cumulative incidenceof severeacute respiratory syn-
dromecoronavirus2 (SARS-CoV-2) infection, as serologic tests
identify both active and past infections.
Methods |This studywas approved by the LosAngeles County
Department of Public Health Institutional ReviewBoard, and
written informed consent was obtained.
We tested for SARS-CoV-2–specific antibodies using a lat-
eral flow immunoassay test (Premier Biotech). Residents of
Figure. Cumulative Seroconversion (Development of SARS-CoV-2 IgM
or IgG Antibodies) Rates byWeek of Study in Patients Receiving Dialysis
and Health CareWorkers
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Individuals were considered seropositive based on the study day in which they
were first found to be seropositive for IgM, IgG, or both. SARS-CoV-2 indicates
severe acute respiratory syndrome coronavirus 2.
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